โรคหลอดเลือดสมองอุดตันจากลิ่มเลือดหัวใจในภาวะหัวใจห้องบนเต้นระริกที่ไม่มีความผิดปกติของลิ้นหัวใจ

Damphant  Nilayon

Authors

Damphant Nilayon Police General Hospital

Keywords:

cardioembolic stroke, atrial fibrillation, anticoagulant

Abstract

Atrial fibrillation (AF) is a major cause of cardioembolic stroke. It is associated with high risk of recurrent stroke, high morbidity and mortality. The risk of cardioembolic stroke in AF is reduced by oral anticoagulant particularly Warfarin. However, currently, several new oral anticoagulants are not only useful in prevention of cardioembolism but are lower the risk of intracranial bleeding. The selection of anticoagulant between the old Warfarin and the new one depending on each patient’s condition together with other risk factors, which has to be managed.

Downloads

Download data is not yet available.

References

Active Investigators. (2009). Effect of clopidogrel added to aspirin in patients with atrial fibrillation. New England Journal of Medicine, 360(20), 2066-2078.

Albers, G. W., Marks, M. P., Kemp, S., Christensen, S., Tsai, J. P., Ortega-Gutierrez, S., . . . Sarraj, A. (2018). Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. New England Journal of Medicine, 378(8), 708-718.

Amarenco, P., Kim, J. S., Labreuche, J., Charles, H., Abtan, J., Béjot, Y., . . . Guidoux, C. (2020). A comparison of two LDL cholesterol targets after ischemic stroke. New England Journal of Medicine, 382(1), 9-19.

American Diabetes Association. (2020). 6 Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care, 43(Suppl 1), S66.

Anderson, D. C., Kappelle, L. J., Eliasziw, M., Babikian, V. L., Pearce, L. A., & Barnett, H. J. M. (2002). Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis. STROKE-DALLAS, 33(8), 1963-1967.

Campbell, B., Ma, H., Ringleb, P. A., Parsons, M. W., Churilov, L., Bendszus, M., . . . EXTEND, ECASS-4, and EPITHET Investigators (2019). Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet (London, England), 394(10193), 139–147. https://doi.org/10.1016/S01406736(19)31053-0

Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., . . . Wang, S. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361(12), 1139-1151.

Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., . . . Ruzyllo, W. (2013). Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 369(22), 2093-2104.

Granger, C. B., Alexander, J. H., Mcmurray, J. J., Lopes, R. D., Hylek, E. M., Hanna, M., . . . Bahit, M. C. (2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 365(11), 981-992.

Johnston, S. C., Amarenco, P., Denison, H., Evans, S. R., Himmelmann, A., James, S., . . . Wang, Y. (2020). Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. New England Journal of Medicine, 383(3), 207-217.

Johnston, S. C., Easton, J. D., Farrant, M., Barsan, W., Conwit, R. A., Elm, J. J., . . . Palesch, Y. Y. (2018). Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. New England Journal of Medicine, 379(3), 215-225.

Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., . . . Brass, L. M. (2016). Pioglitazone after ischemic stroke or transient ischemic attack. New England Journal of Medicine, 374, 1321-1331.

Lip, G. Y., Banerjee, A., Boriani, G., En Chiang, C., Fargo, R., Freedman, B., . . . Patel, S. (2018). Antithrombotic therapy for atrial fibrillation: Chest guideline and expert panel report. Chest, 154(5), 1121-1201.

Lip, G. Y., Keshishian, A., Li, X., Hamilton, M., Masseria, C., Gupta, K., . . . Pan, X. (2018). Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: The ARISTOPHANES study. Stroke, 49(12), 2933-2944.

Lip, G. Y., & Lane, D. A. (2015). Stroke prevention in atrial fibrillation: A systematic review. Jama, 313(19), 1950-1962.

Li, Y. G., & Lip, G. Y. (2018). Anticoagulation resumption after intracerebral hemorrhage. Current Atherosclerosis Reports, 20(7), 32.

Mac Grory, B., Flood, S., Schrag, M., Paciaroni, M., & Yaghi, S. (2019). Anticoagulation resumption after stroke from atrial fibrillation. Current atherosclerosis reports, 21(8), 29.

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., . . . Wiklund, O. (2019). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal, 00, 1-78. doi:10.1093/eurheartj/ehz455

Marini, C., De Santis, F., Sacco, S., Russo, T., Olivieri, L., Totaro, R., & Carolei, A. (2005). Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: Results from a population-based study. Stroke, 36(6), 1115-1119.

Mtwesi, V., & Amit, G. (2019). Stroke prevention in atrial fibrillation: The role of oral anticoagulation. Medical Clinics, 103(5), 847-862.

Nogueira, R. G., Jadhav, A. P., Haussen, D. C., Bonafe, A., Budzik, R. F., Bhuva, P., . . . Sila, C. A. (2018). Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. New England Journal of Medicine, 378(1), 11-21.

Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., . . . Becker, R. C. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 365(10), 883-891.

Saxena, R., Lewis, S., Berge, E., Sandercock, P. A., Koudstaal, P. J., & International Stroke Trial Collaborative Group. (2001). Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke, 32(10), 2333-2337.

Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. (2006). High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine, 355(6), 549-559.

Thomalla, G., Simonsen, C. Z., Boutitie, F., Andersen, G., Berthezene, Y., Cheng, B., . . . Ford, I. (2018). MRI-guided thrombolysis for stroke with unknown time of onset. New England Journal of Medicine, 379(7), 611-622.

Toyoda, K., Uchiyama, S., Yamaguchi, T., Easton, J. D., Kimura, K., Hoshino, H., . . . Naritomi, H. (2019). Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: A multicentre, open-label, randomised controlled trial. The Lancet Neurology, 18(6), 539-548.

Wang, Y., Wang, Y., Zhao, X., Liu, L., Wang, D., Wang, C., . . . Jia, J. (2013). Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine, 369, 11-19.

Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1987). Atrial fibrillation: A major contributor to stroke in the elderly: The Framingham study. Archives of internal medicine, 147(9), 1561-1564.

Yang, P., Zhang, Y., Zhang, L., Zhang, Y., Treurniet, K. M., Chen, W., . . . Yin, C. (2020). Endovascular thrombectomy with or without intravenous alteplase in acute stroke. New England Journal of Medicine, 382(21), 1981-1993.